Applied Research Systems Ars Holding N.v.

Istituto Farmacologico Serono S.p.a.

Instituto Fermacologio Serono Spa

Francesco Borrelli

Fabrizio Martelli

Francesco Antonetti

Silvia Donini

Alessandra Boe

Marina Ziche

Renato Mastrangeli

Mauro D'Antonio

The present invention relates to the use of a TNF Receptor together with a steroid hormone to produce a pharmaceutical composition for the treatment of lethal bacterial and viral infections as well as autoimmune and inflammatory diseases. It also relates to said pharmaceutical compositions for the simultaneous, separate or sequential use of its active ingredients for the above specified treatment. In particular, it relates to the use of TBP-1 together with dehydroepiandrosterone (DHEA) or its metabolites to produce a pharmaceutical composition for the treatment of septic shock.

TNF receptor and steroid hormone in a combined therapy

The present invention refers to the use of Compound B as angiogenic agent in combination with human growth factors.

Compound B as angiogenic agent in combination with human growth factors

Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected from among several classes but preferably are soluble TNF receptors. The antagonists are useful for the regression of endometriotic lesions and, if combined with other active ingredients, for amelioration of related disorders, like infertility.

Tumor necrosis factor antagonists and their use in endometriosis

Component B as cicatrizant

The toxic effects caused by anthraquinone drugs, particularly by antitumor anthraquinone drugs, are inhibited or reduced by administering Orgotein in a quantity sufficient to inhibit or reduce the superoxide radicals which are produced by the above mentioned drugs.

Reduction of the toxic effects caused by anthraquinone drugs

The association of a fibrinolytic agent and of a diffusion factor has been shown very useful in the treatment of myocardial infarction. It has been shown that it is very useful to administer urokinase and hyaluronidase in the quantity ratio of at least 8 to 1, the quantity of each compound being expressed in the appropriate international units.

Growing community of inventors

Rome, Italy

Francesco Borrelli